Processa Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Processa Pharmaceuticals

30/03/2023 22:56

* Processa Pharmaceuticals Inc  PCSA.OQ  reported a
quarterly
adjusted loss of 36 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for a loss of 32 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Processa Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 80 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Processa Pharmaceuticals Inc shares had fallen by 58.7%
this
quarter.
    * The company reported a quarterly loss of $13.01 million.
    * Wall Street's median 12-month price target for Processa
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 09:56 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.32          -0.36          Missed
 Sep. 30 2022      -0.34          -0.37          Missed
 Jun. 30 2022      -0.20          -0.32          Missed
 Mar. 31 2022      -0.21          -0.20          Beat